Covalent drugs in development for immune-mediated diseases

被引：3

作者：

Sung, Leonard ^{[1
]}

机构：

[1] Sanofi Co, Principia Biopharma, San Francisco, CA 94080 USA

来源：

DESIGN OF COVALENT-BASED INHIBITORS | 2021年 / 56卷

关键词：

BRUTONS TYROSINE KINASE; IRREVERSIBLE INHIBITORS; DISCOVERY; IBRUTINIB; DESIGN; JAK3; BTK;

D O I：

10.1016/bs.armc.2021.03.001

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

引用

页码：33 / 74

页数：42

共 49 条

[1] Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity [J].

Anastassiadis, Theonie ;

Deacon, Sean W. ;

Devarajan, Karthik ;

Ma, Haiching ;

Peterson, Jeffrey R. .

NATURE BIOTECHNOLOGY, 2011, 29 (11) :1039-U117

[2] Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase [J].

Angst, Daniela ;

Gessier, Francois ;

Janser, Philipp ;

Vulpetti, Anna ;

Walchli, Rudolf ;

Beerli, Christian ;

Littlewood-Evans, Amanda ;

Dawson, Janet ;

Nuesslein-Hildesheim, Barbara ;

Wieczorek, Grazyna ;

Gutmann, Sascha ;

Scheufler, Clemens ;

Hinniger, Alexandra ;

Zimmerlin, Alfred ;

Funhoff, Enrico G. ;

Pulz, Robert ;

Cenni, Bruno .

JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (10) :5102-5118

[3] Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies [J].

Bauer, Renato A. .

DRUG DISCOVERY TODAY, 2015, 20 (09) :1061-1073

[4] Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers [J].

Becker, Andreas ;

Martin, Emily C. ;

Mitchell, David Y. ;

Grenningloh, Roland ;

Bender, Andrew T. ;

Laurent, Julien ;

Mackenzie, Harald ;

Johne, Andreas .

CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (02) :325-336

[5]

Bradshaw JM, 2015, NAT CHEM BIOL, V11, P525, DOI [10.1038/nchembio.1817, 10.1038/NCHEMBIO.1817]

[6] Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances [J].

Bryan, Marian C. ;

Rajapaksa, Naomi S. .

JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (20) :9030-9058

[7] Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia [J].

Byrd, J. C. ;

Brown, J. R. ;

O'Brien, S. ;

Barrientos, J. C. ;

Kay, N. E. ;

Reddy, N. M. ;

Coutre, S. ;

Tam, C. S. ;

Mulligan, S. P. ;

Jaeger, U. ;

Devereux, S. ;

Barr, P. M. ;

Furman, R. R. ;

Kipps, T. J. ;

Cymbalista, F. ;

Pocock, C. ;

Thornton, P. ;

Caligaris-Cappio, F. ;

Robak, T. ;

Delgado, J. ;

Schuster, S. J. ;

Montillo, M. ;

Schuh, A. ;

de Vos, S. ;

Gill, D. ;

Bloor, A. ;

Dearden, C. ;

Moreno, C. ;

Jones, J. J. ;

Chu, A. D. ;

Fardis, M. ;

McGreivy, J. ;

Clow, F. ;

James, D. F. ;

Hillmen, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (03) :213-223

[8] Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia [J].

Byrd, John C. ;

Harrington, Bonnie ;

O'Brien, Susan ;

Jones, Jeffrey A. ;

Schuh, Anna ;

Devereux, Steve ;

Chaves, Jorge ;

Wierda, William G. ;

Awan, Farrukh T. ;

Brown, Jennifer R. ;

Hillmen, Peter ;

Stephens, Deborah M. ;

Ghia, Paolo ;

Barrientos, Jacqueline C. ;

Pagel, John M. ;

Woyach, Jennifer ;

Johnson, Dave ;

Huang, Jane ;

Wang, Xiaolin ;

Kaptein, Allard ;

Lannutti, Brian J. ;

Covey, Todd ;

Fardis, Maria ;

McGreivy, Jesse ;

Hamdy, Ahmed ;

Rothbaum, Wayne ;

Izumi, Raquel ;

Diacovo, Thomas G. ;

Johnson, Amy J. ;

Furman, Richard R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (04) :323-332

[9] Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases [J].

Caldwell, Richard D. ;

Qiu, Hui ;

Askew, Ben C. ;

Bender, Andrew T. ;

Brugger, Nadia ;

Camps, Montserrat ;

Dhanabal, Mohanraj ;

Dutt, Vikram ;

Eichhorn, Thomas ;

Gardberg, Anna S. ;

Goutopoulos, Andreas ;

Grenningloh, Roland ;

Head, Jared ;

Healey, Brian ;

Hodous, Brian L. ;

Huck, Bayard R. ;

Johnson, Theresa L. ;

Jones, Christopher ;

Jones, Reinaldo C. ;

Mochalkin, Igor ;

Morandi, Federica ;

Ngan Nguyen ;

Meyring, Michael ;

Potnick, Justin R. ;

Santos, Dusica Cvetinovic ;

Schmidt, Ralf ;

Sherer, Brian ;

Shutes, Adam ;

Urbahns, Klaus ;

Follis, Ariele Viacava ;

Wegener, Ansgar A. ;

Zimmerli, Simone C. ;

Liu-Bujalski, Lesley .

JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (17) :7643-7655

[10] Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants [J].

Catlett, Ian M. ;

Nowak, Miroslawa ;

Kundu, Sudeep ;

Zheng, Naiyu ;

Liu, Ang ;

He, Bing ;

Girgis, Ihab G. ;

Grasela, Dennis M. .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (09) :1849-1859

← 1 2 3 4 5 →